繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Jaguar Health Reports Issue of Hong Kong Patent for Short Bowel Syndrome Treatment Methods

2024-08-19 23:29

11:29 AM EDT, 08/19/2024 (MT Newswires) -- Jaguar Health (JAGX) said Monday Hong Kong's Intellectual Property Department has issued a new patent to its family firm, Napo Pharmaceuticals, for methods for treating short bowel syndrome, bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, its prescription drug.

"We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said CEO Lisa Conte.

Price: 1.28, Change: +0.01, Percent Change: +0.47

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。